Tube Feeding in Children Having a Bone Marrow Transplant

Sponsor
Institute of Child Health (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04804631
Collaborator
National Institute for Health Research, United Kingdom (Other), Great Ormond Street Hospital for Children NHS Foundation Trust (Other)
43
1
25.5
1.7

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the problems and a range of nutritional and clinical outcomes that occur with two feeding tubes used by children having a bone marrow transplant. Children and parents will also be interviewed to ask about their experiences of tube feeding.

Detailed Description

Background: Bone marrow transplant (BMT) is the only potentially curative treatment for children with malignant and non-malignant diseases. Chemotherapy provided during BMT causes side-effects including diarrhoea and vomiting meaning all children become unable to eat and require tube feeding. All 16 centres in the UK use a nasogastric tube. Great Ormond Street Hospital offer families a gastrostomy as an alternative. Minimal published literature exists on gastrostomies in this population.

Aims: Investigate complications, outcomes and family experiences of gastrostomy tubes in paediatric BMT.

Objectives:
  1. Survey current nutrition practices, use and opinions towards gastrostomy tubes in UK paediatric BMT centres.

  2. Compare clinical outcomes and complications occurring from gastrostomy versus nasogastric tubes in children during BMT.

  3. Investigate decision making and experiences of families regarding tube feeding.

Methods: A multiphase, convergent parallel mixed methods study across 3 work packages (WPs).

  1. Survey: A survey will be sent to a dietitian, nurse and doctor (the staff involved in tube feeding) in each UK paediatric BMT centre. Questions will focus on nutrition practices, and current use and opinions of gastrostomies.

  2. Prospective cohort study: Outcomes will be compared between children fed via gastrostomy versus nasogastric tube from admission to six months post-BMT. All children transplanted over one year at one centre will be included. Outcomes including complications occurring with both tubes, dietary intake and anthropometry will be investigated. Anticipated sample size is 9-15 children fed via gastrostomy, 30-50 via nasogastric tube.

  3. Family interviews: Families from WP 2 will be invited to be interviewed at two times; on admission to discuss why they did or did not choose a gastrostomy, and one month after discharge to discuss their experience of tube feeding. Creative methods including drawing and scrapbooks will be used during children's interviews to help them articulate their thoughts. Parents will take part in semi-structured interviews.

Study Design

Study Type:
Observational
Actual Enrollment :
43 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Mixed Methods Study Investigating Complications, Outcomes and Family Experiences of Gastrostomy Feeding in Paediatric Allogeneic Bone Marrow Transplantation
Actual Study Start Date :
Mar 15, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Gastrostomy tube

Prophylactic gastrostomy placed prior to bone marrow transplant.

Device: Enteral feeding tubes
Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.

Nasogastric tube

Nasogastric tube placed during admission.

Device: Enteral feeding tubes
Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.

Outcome Measures

Primary Outcome Measures

  1. Weight Z-score [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Change in weight Z-score between groups. Measured using ward scales.

Secondary Outcome Measures

  1. Gastrostomy tube complications [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to tube removal or six months post-transplant, whichever comes first (6 months)]

    Categorical reporting of the incidence of any complications occurring with the gastrostomy tube e.g. infection, dislodgement, blockage

  2. Nasogastric tube complications [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to tube removal or six months post-transplant, whichever comes first (6 months)]

    Categorical reporting of the incidence of any complications occurring with the nasogastric tube e.g. dislodgement, blockage

  3. Height Z-score [Measured monthly from admission to six months post-transplant (6 months)]

    Change in height Z-score between groups. Measured using ward stadiometer.

  4. Body mass index (BMI) Z-score [Measured monthly from admission to six months post-transplant (6 months)]

    Change in BMI Z-score between groups. Weight and height will be combined to report BMI in kg/m^2 and converted to Z-scores.

  5. Mid-upper-arm circumference (MUAC) Z-score [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Change in MUAC Z-score between groups. Measured using ward measuring tape.

  6. Overall survival [Measured for all children at day-100 post-transplant]

    Percentage of children alive (with death from any cause) 100 days post-bone marrow transplant

  7. Non-relapse mortality [Measured for all children at day-100 post-transplant]

    Percentage of children alive (with death not caused by disease relapse) 100 days post-bone marrow transplant

  8. Graft-versus-host disease grade III-IV [Measured for all children at day-100 post-transplant]

    Percentage of children with grade III-IV graft-versus-host disease (measured using modified Gluckberg classification) 100 days post-bone marrow transplant

  9. Gastrointestinal graft-versus-host disease [Measured for all children at day-100 post-transplant]

    Percentage of children with gut graft-versus-host disease (measured using modified Gluckberg classification) 100 days post-bone marrow transplant

  10. Calorie intake [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Average intake of calories (total kcal intake and kcals/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month.

  11. Protein intake [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Average intake of protein (total protein intake and grams/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month.

  12. Fluid intake [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Average intake of fluid (total fluid intake and ml/kg) provided from oral, enteral and parenteral nutrition, averaged over 3-days, measured from the hospital's electronic patient records during the bone marrow transplant admission, and thereafter once the child is at home from 3-day food diaries recorded once per month.

  13. Duration of enteral nutrition [Measured from admission for bone marrow transplant to tube removal or discharge home post-transplant, whichever comes first. (Hospital admission is usually 3 months)]

    Total number of days enteral nutrition is provided during admission for bone marrow transplant

  14. Duration of parenteral nutrition [Measured from admission for bone marrow transplant to tube removal or discharge home post-transplant, whichever comes first. (Hospital admission is usually 3 months)]

    Total number of days parenteral nutrition is provided during admission for bone marrow transplant

  15. Use of enteral feeding tube [Measured weekly for six weeks from admission for bone marrow transplant, and monthly thereafter to six months post-transplant (6 months)]

    Categorical description of what the enteral feeding tube is used for. Categories include: "Not in use", "Nutrition only", "Medicines only", "Fluids only", "Nutrition & medicines", "Medicines & fluids", "Nutrition, medicines & fluids".

  16. Blood copper level [Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months)]

    Change in blood copper level (micromol/L) during admission for bone marrow transplant

  17. Blood selenium level [Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months)]

    Change in blood selenium level (micromol/L) during admission for bone marrow transplant

  18. Blood zinc level [Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months)]

    Change in blood zinc level (micromol/L) during admission for bone marrow transplant

  19. Blood vitamin A level [Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months)]

    Change in blood vitamin A level (micromol/L) during admission for bone marrow transplant

  20. Blood vitamin E level [Measured monthly from admission for bone marrow transplant until the child is discharged home following the transplant (hospital admission is usually 3 months)]

    Change in blood vitamin E level (micromol/L) during admission for bone marrow transplant

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 13 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admitted to the centre during the study period for an allogeneic bone marrow transplant (BMT) for any diagnosis.

  • Receiving any conditioning regimen, donor type and stem cell source.

  • Children admitted for their second or more BMT.

  • Children admitted on an established enteral tube feeding regimen.

  • NHS patients.

Exclusion Criteria:
  • Children receiving first-line, prophylactic, parenteral nutrition as this is not the standard nutrition pathway of most children receiving BMT at the centre. This is usually given in specific circumstances such as children receiving cord blood transplants or those with gastrointestinal diseases.

  • Autologous BMT, including children receiving chimeric antigen receptor T-cell therapy (CAR-T).

  • No feeding tube placed and no nutrition support required from tube feeding or parenteral nutrition. Children rarely do not require any form of nutrition support.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Great Ormond Street Hospital London United Kingdom WC1N3JH

Sponsors and Collaborators

  • Institute of Child Health
  • National Institute for Health Research, United Kingdom
  • Great Ormond Street Hospital for Children NHS Foundation Trust

Investigators

  • Principal Investigator: Faith Gibson, Professor, Great Ormond Street Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Institute of Child Health
ClinicalTrials.gov Identifier:
NCT04804631
Other Study ID Numbers:
  • 19SH04
First Posted:
Mar 18, 2021
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institute of Child Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022